Drug Trial Radar · NCT02611492
A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults
Last checked: Nov 20, 2026Latest source record: Oct 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
265
Planned (sponsor's estimate)
Start
Apr 2016
Primary completion
Dec 2020
Study completion Dec 2025
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 59 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Primary objective is to assess the non-inferiority of the experimental arm (arm B) compared to the control arm (arm A) in terms of Major Molecular Response (MMolR) after the 4th cycle (MRD4) in patients aged 18-59 years old with de novo Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL)
Conditions
- Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia
Interventions
NilotinibDrug
400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
MethotrexateDrug
1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
Aracytine (Ara C)Drug
Age\<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age\>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
Granulocyte Colony-Stimulating Factor (G-CSF)Drug
5µg/kg/d (SC) D6 until neutrophils \> 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
DepomedrolDrug
40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
DexamethasoneDrug
40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
VincristineDrug
2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
ImatinibDrug
300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
6 Mercaptopurine (6MP)Drug
60 mg/m2 per os, D1 to D14, interphase
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Molecular Response (MMolR)Time frame: 4 cycles (4 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hopital Saint Louis
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.